Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

Please Try Again

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

News Focus

LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)

Bullboard - Stock Discussion Forum NervGen Pharma Corp V.NGEN

Alternate Symbol(s): NGENF

Healthcare

NervGen Pharma Corp. is a clinical-stage biotech company. The Company is engaged in discovery, development and commercialization of pharmaceutical products for the treatment of nervous system damage due to injury or disease. The Company is advancing its lead compound, NVG-291, for the treatment of spinal cord injury (SCI), Alzheimer’s disease (AD) and multiple sclerosis (MS). Its NVG-291 is a... see more

Add To Watchlist

Bullboard (TSXV:NGEN)

View:

Comment by deepoil0808on Mar 19, 2024 12:40pm

RE:RE:Brian Bayley sold 100,000 shares at $ 3/share

Agreed, he dumped 30% of his holdings or $ 450,000 worth of stock. That is a big chunk!!! Why would he do this? Unless..... My personal opinion,

120

Discussion

Comment by CheckingRealityon Mar 19, 2024 11:38am

RE:Brian Bayley sold 100,000 shares at $ 3/share

Something is very fishy!

Discussion

Pharmaceutical Tech Co Reports 2.7X Revenue Growth Year-Over-Year at US $24 Million

posted Nov 21, 2024 9:00am by Innocan Pharma Corp

"Our strong operational and financial momentum continued throughout 2024 and now in the third quarter, we again demonstrated solid financial results. We are pleased to report nine consecutive quarters of continuous revenue growth. Our online platform continues to perform exceptionally well, contributing to our strong nine-month revenue growth of 174% YoY ...read more

Post by deepoil0808on Mar 18, 2024 5:53pm

Brian Bayley sold 100,000 shares at $ 3/share

Brian Baylet sold 150,000 shares of the company: 100,000 shares from options at $ 3 per share and, 50,000 shares from his core holdings Owns +/- 333,000 shares. What prompted this big ...more

437

Discussion

Post by greenlandon Mar 18, 2024 10:38am

No comment

If insider trading was done because of a the red flag then justice will come? Nervgen Pharma Corp (NGEN-X) Insider Trade Summaries - The Globe and Mail

132

Comment by deepoil0808on Mar 16, 2024 5:42pm

RE:Something....

Facts that observers can see the progress makes it difficult to keep a lid on results. Plunging price tells me that results do not appear to be favorable. Good Luck,

115

Discussion

Post by CheckingRealityon Mar 15, 2024 12:22pm

Something....

is very wrong with this stock.

142

Discussion

Post by deepoil0808on Mar 14, 2024 4:32pm

200 day moving average $ 2.13/share

Looks like we are heading towards the 200 day moving average of $2.13 per share. Pretty steep slope so far. If it breaks this support, then it confirms that the trials may not be ...more

173

Post by deepoil0808on Mar 13, 2024 6:07pm

Is there a leak? Drop from $ 3.80 to $ 2.89....

Trading seems to indicate a loss in confidence, Is there is leak? Good Luck

108

(0)
•••

Post by PressReleaseon Feb 21, 2024 8:02am

New Press Release - NervGen Pharma Recognized as a Top 50 TSX Venture Exchange Company

Vancouver, British Columbia--(Newsfile Corp. - February 21, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, has been recognized by the TSX Venture Exchange as a 2023...read article.

(0)
•••

Post by PressReleaseon Feb 20, 2024 5:37pm

New Press Release - NervGen Pharma Grants Stock Options

Vancouver, British Columbia--(Newsfile Corp. - February 20, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, today announced that it has granted incentive stock...read article.

(0)
•••

Post by PressReleaseon Feb 15, 2024 8:48am

New Press Release - NervGen Pharma on Track to Complete Enrollment, Deliver Data Readout in Phase 1b/2a Clinical Trial for NVG-291 in Spinal Cord Injury

On track to complete enrollment of the chronic cohort in Q2 2024Data readout from chronic cohort expected in Q3 2024Planning underway to make NVG-291 available to placebo-treated subjects following cohort completion Vancouver, British Columbia--(Newsfile Corp. - February 15, 2024) - NervGen...read article.

Post by stargazer1on Feb 07, 2024 12:35am

We received Fast Track approval Oct. 2023, but ...

October 23, 2023) - NervGen Pharma Corporation announced today that the U.S. Food and Drug Administration has granted Fast Track designation for its proprietary lead compound, NVG-291, in individuals ...more

375

Comment by RHertigon Feb 06, 2024 2:39pm

RE:Clinical trial & how it would lead to immediate approval.

Fast track is the terminology.

186

Discussion

Post by stargazer1on Feb 05, 2024 4:50pm

Clinical trial & how it would lead to immediate approval.

NervGen is conducting a Phase 1a/2b clinical trial of NVG-291, which is better than a phase lll trial and could get the FDA to approve NVG-291 in short order. Previously there were: Phase ...more

526

Discussion

Comment by rdgeo44on Feb 02, 2024 7:32pm

RE:NGENF to be top biotech of 2024. Clinical trial results leak

Apart from the nice bump in the share price today, thank you for posting this article. I almost feel guilty when i look at the SP as I have a more important reason for supporting this company, that is ...more

408

Discussion

The Market Update

< Previous bulletin

Next bulletin >

A daily snapshot of everything
from market open to close.

< Previous

Next >

Dealroom for high-potential pre-IPO opportunities

Become a member today, It's free!

Bullboard - Stock Discussion Forum NervGen Pharma Corp V.NGEN

Alternate Symbol(s): NGENF

Bullboard (TSXV:NGEN)

RE:RE:Brian Bayley sold 100,000 shares at $ 3/share

RE:Brian Bayley sold 100,000 shares at $ 3/share

Pharmaceutical Tech Co Reports 2.7X Revenue Growth Year-Over-Year at US $24 Million

Brian Bayley sold 100,000 shares at $ 3/share

No comment

RE:Something....

Something....

200 day moving average $ 2.13/share

Is there a leak? Drop from $ 3.80 to $ 2.89....

New Press Release - NervGen Pharma Recognized as a Top 50 TSX Venture Exchange Company

New Press Release - NervGen Pharma Grants Stock Options

New Press Release - NervGen Pharma on Track to Complete Enrollment, Deliver Data Readout in Phase 1b/2a Clinical Trial for NVG-291 in Spinal Cord Injury

We received Fast Track approval Oct. 2023, but ...

RE:Clinical trial & how it would lead to immediate approval.

Clinical trial & how it would lead to immediate approval.

RE:NGENF to be top biotech of 2024. Clinical trial results leak

Featured News Links

Discover Options Trading Strategies to Minimize your Tax Burden

Become a member today, It's free!

Sign In

Send my password

Become a member today, It's free!

Bullboard - Stock Discussion Forum NervGen Pharma Corp V.NGEN

Alternate Symbol(s): NGENF

Join the community and start posting on the bullboards today. It's free.

Create a portfolio watchlist today. It's free.

Bullboard (TSXV:NGEN)

Featured News Links